Trials / Terminated
TerminatedNCT02944864
A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics
Phase I Study of Tolerance and Pharmacokinetics of TQ-B3395 in Patients With Advanced Cancer
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To study the pharmacokinetic characteristics of TQ-B3395 in the human body, recommend a reasonable regimen for subsequent research.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3395 | TQ-B3395 p.o. qd |
Timeline
- Start date
- 2017-09-13
- Primary completion
- 2021-05-23
- Completion
- 2022-09-15
- First posted
- 2016-10-26
- Last updated
- 2024-09-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02944864. Inclusion in this directory is not an endorsement.